86 related articles for article (PubMed ID: 8489566)
1. [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].
Vens-Cappell B; Hilgenstock C; Gellert M; Kühle K; Reifferscheid I; Winckler P; Bührens KG
Arzneimittelforschung; 1993 Mar; 43(3):346-50. PubMed ID: 8489566
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics].
Vens-Cappell B; Berndt P; Hilgenstock C; Kühle K; Reifferscheid I; Schütt S; Bührens KG
Arzneimittelforschung; 1993 Mar; 43(3):351-6. PubMed ID: 8489567
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacokinetics of two oral bezafibrate preparations.
Cadorniga R; Herrero R; Pastoriza P; Molina IT; Gutierrez JA; Iglesias JJ
Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():261-7. PubMed ID: 1820889
[TBL] [Abstract][Full Text] [Related]
4. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man.
Gandini R; Assereto R; Castoldi D; Cunietti E; Garanzelli P; Monzani W
Int J Clin Pharmacol Res; 1987; 7(2):149-55. PubMed ID: 3583496
[TBL] [Abstract][Full Text] [Related]
5. A study on the relative bioavailability of a sustained-release formulation of diclofenac sodium.
Suleiman MS; Najib N; el-Sayed Y; Hasan M; Abdulahameed M
Int J Clin Pharmacol Ther Toxicol; 1989 Jun; 27(6):276-9. PubMed ID: 2737796
[TBL] [Abstract][Full Text] [Related]
6. Sustained-release verapamil: multiple-dose pharmacokinetic comparison of 120-mg and 240-mg tablets and the effect of halving a 240-mg tablet.
McEwen J; Durnin C; McMurdo ME; Moreland TA
J Cardiovasc Pharmacol; 1989; 13 Suppl 4():S57-9. PubMed ID: 2475689
[TBL] [Abstract][Full Text] [Related]
7. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
[TBL] [Abstract][Full Text] [Related]
8. [The pharmacokinetics and bioequivalence of acipimox sustained-release tablets after a single and multiple oral administration in healthy dogs].
Yang XG; Nie SF; Bai HJ; Zhang GJ; Pan WS
Yao Xue Xue Bao; 2005 May; 40(5):457-61. PubMed ID: 16220793
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and bioavailability of four modified-release ursodeoxycholic acid preparations for once-a-day administration.
Simoni P; Sabatini L; Baraldini M; Mirasoli M; Roda A; Roda E
Int J Clin Pharmacol Res; 2002; 22(2):37-45. PubMed ID: 12503774
[TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg.
Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP
J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658
[TBL] [Abstract][Full Text] [Related]
11. Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability.
Zmeili S; Hasan M; Najib N; Sallam E; Deleq S; Shubair M
Int J Clin Pharmacol Ther; 1996 Dec; 34(12):564-70. PubMed ID: 8996854
[TBL] [Abstract][Full Text] [Related]
12. [Pharmacokinetics and relative bioavailability of KC-404 sustained release tablets in healthy volunteers].
Li T; Pang Y; Wang Z; Jia Y; Cheng Q; Sun J
Sichuan Da Xue Xue Bao Yi Xue Ban; 2003 Jul; 34(3):541-3. PubMed ID: 12910715
[TBL] [Abstract][Full Text] [Related]
13. Development and pharmacokinetics of a new sustained-release formulation of diltiazem.
Thiercelin JF; Necciari J; Caplain H; Cournot A; Combes M; Desmolin H; Flouvat B
J Cardiovasc Pharmacol; 1990; 16 Suppl 1():S31-7. PubMed ID: 1706011
[TBL] [Abstract][Full Text] [Related]
14. [Absolute bioavailability of a special sustained-release acetylsalicylic acid formulation].
Lücker PW; Swoboda M; Wetzelsberger N
Arzneimittelforschung; 1989 Mar; 39(3):391-4. PubMed ID: 2757664
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects.
Raz I; Ben-David J; Hussein Z; Samara E
Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):206-8. PubMed ID: 3403100
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: results of two randomized studies in patients with Parkinson's disease.
Tompson DJ; Vearer D
Clin Ther; 2007 Dec; 29(12):2654-66. PubMed ID: 18201581
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
Wangemann M; Retzow A; Vens-Cappell B
Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the absorption from three ibuprofen formulations.
Regazzi BM; Rondanelli R; Ciaroelli L; Bartoli AL; Rampini A
Int J Clin Pharmacol Res; 1986; 6(6):469-73. PubMed ID: 3804520
[TBL] [Abstract][Full Text] [Related]
19. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of 3 different diets on the bioavailability of 2 sustained release theophylline matrix tablets.
Gai MN; Isla A; Andonaegui MT; Thielemann AM; Seitz C
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):565-71. PubMed ID: 9455715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
